Recent analyst reports have adjusted price targets for several stocks, including Fortrea, Docebo, and Silence Therapeutics. We examine these changes and their potential impact. Read more...

Recent analyst activity includes a buy rating for Jamf and lowered earnings estimates for Fortrea, Verisk, Teladoc Health, and VSE, all involving insights from William Blair. CentralReach is also exploring a sale with William Blair's assistance. Read more...

William Blair reaffirmed ratings for AvePoint and Biodesix, reiterated a "market perform" for Fortrea, and issued Q1 earnings forecast for Rocket Pharmaceuticals. Read more...